Intersect ENT gets FDA approval for Propel

08/15/2011 | Medscape (free registration)

The FDA has approved Intersect ENT's Propel, an implantable mometasone furoate delivery system for chronic sinusitis. The device helps prevent postsurgery sinus obstruction, reduce inflammation and curb polyp formation in patients, according to three clinical trials conducted.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT